The Global Health Body Issues Concern Over Acute Scarcity of Obesity Medications
Fewer than a tenth of patients eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it releases its first recommendations on the medications.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments.
According to estimates, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a lifelong illness that can be managed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and logistical bottlenecks are major obstacles to widespread access to the injections that can help people shift considerable body mass, notes the agency.
Weight-Loss Drug Scarcity
Even in the present most optimistic case, the manufacturing of GLP-1 therapies might only reach approximately 100 million people – less than 10% of eligible patients, per the WHO.
The guideline urges governments and firms to increase access, by approaches including voluntary licensing.
A patent on a key compound – the core component of a leading brand – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Function
These medications imitate a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so people eat less.
Patients usually start to lose weight in the initial weeks of beginning the regular doses.
Studies points to users may put most of the weight back on a year later of halting the treatment, as their typical appetite come back.
To be carrying excess weight increases your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight concerns individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, per the health agency.
